Study design
adenocarcinoma, Cancer
ADENOCARCINOMA, CANCER
This is a single-center, single arm, phase II clinical trial for patients with histologically proven gastric or gastroesophageal junction (GEJ) (Siewert 3) adenocarcinoma with positive peritoneal cytology or PC. The primary treatment is iterative paclitaxel NIPEC with systemic paclitaxel and 5-fluorouracil after three months of standard of care systemic chemotherapy. The ongoing study is approved by the institutional review board of University of California Irvine (UCI) [HS#2020–6178] and is supported by the Stern Center Clinical Trials Office at UCI and an UCI Cancer Center anti-cancer challenge grant. The trial was registered under clinical trials.gov; Identifier: NCT04762953 on 21/02/2021. All study methods are performed in accordance with the relevant guidelines and regulations (Declaration of Helsinki).